Benefits of minimal residual disease negativity in the therapy of chronic lymphocytic leukemia.
Kay
Neil E
NE
Mayo Clinic College of Medicine, Rochester, MN, USA.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005434:Flow Cytometry; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000175:diagnosis / Q000188:drug therapy*; D018365:Neoplasm, Residual / Q000175:diagnosis; D016133:Polymerase Chain Reaction; D011379:Prognosis; D012680:Sensitivity and Specificity; D015996:Survival Rate
D000970:Antineoplastic Agents